ReviewCureus2022
A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer.
Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics-Where We Are at and Where We Are Heading: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Preclinical Theranostic Study ofACS omega · 2026Article
- Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody-Drug Conjugates.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Lead radionuclides for theranostic applications in nuclear medicine: from atom to bedside.Theranostics · 2026Review
- Compton Imaging of Ac-225 In Pre-clinical Phantoms With a 3D-positioning CZT Camera.IEEE transactions on radiation and plasma medical sciences · 2026Article
- Combined radioligand therapy and immunotherapy for cancer: research advances and translational challenges.Frontiers in pharmacology · 2026Review
- PSMA-Targeted Radiolabeled Peptide for Imaging and Therapy in Prostate Cancer: Preclinical Evaluation of Biodistribution and Therapeutic Efficacy.International journal of molecular sciences · 2025Article
- Radionuclides Landscape in Prostate Cancer Theranostics.International journal of molecular sciences · 2025Review
- Radiotheranostic landscape: A review of clinical and preclinical development.European journal of nuclear medicine and molecular imaging · 2025Review
- Hematological toxicity of [EJNMMI radiopharmacy and chemistry · 2025Article
- Preclinical Comparison of [Molecular pharmaceutics · 2025Article
- The efficacy and safety ofFrontiers in oncology · 2025Article
- Improvement of End-of-Synthesis Radiochemical Purity ofPharmaceutics · 2024Article
- Decreased levels of PTCSC3 promote the deterioration of prostate cancer and affect the prognostic outcome of patients through sponge miR-182-5p.BMC urology · 2024Article
- Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of theMolecules (Basel, Switzerland) · 2024Article
- Radiomics and Artificial Intelligence in Radiotheranostics: A Review of Applications for Radioligands Targeting Somatostatin Receptors and Prostate-Specific Membrane Antigens.Diagnostics (Basel, Switzerland) · 2024Review
- [Theranostics · 2024Article
- Highlights on U.S. FDA-approved fluorinated drugs over the past five years (2018-2022).European journal of medicinal chemistry · 2023Review
- The Application of Radiolabeled Targeted Molecular Probes for the Diagnosis and Treatment of Prostate Cancer.Korean journal of radiology · 2023Review
- Nanoparticle-Based Radioconjugates for Targeted Imaging and Therapy of Prostate Cancer.Molecules (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of prostate-specific membrane antigen (PSMA) ligands labeled with radionuclides is a ground-breaking achievement in the management of prostate cancer. With the increasing use of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.